Antiangiogenic therapy of brain tumors: The role of bevacizumab

Neurological Sciences

Volumn 35, Issue 4, 2014, Pages 507-514

  Trevisan, Elisa ^a   Bertero, Luca ^a   Bosa, Chiara ^a   Magistrello, Michela ^a   Pellerino, Alessia ^a   Rudà, Roberta ^a   Soffietti, Riccardo ^a  

^a AOU Città della Salute e della Scienza University Hospital   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Glioblastoma; High grade glioma; VEGF

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CORTICOSTEROID; CYTOTOXIC AGENT; ENDOSTATIN; ERLOTINIB; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; NEUROPILIN 1; NITROSOUREA; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TEMOZOLOMIDE; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC THERAPY; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CAPILLARY DENSITY; GLIOBLASTOMA; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84897408875     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1627-6     Document Type: Review

References (66)

1. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
4. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
7. Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro Oncol 15:4-27
8. Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15:339-347
9. Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372 (Pubitemid 26023356)
10. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622 (Pubitemid 47093931)
11. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86:1221-1232 (Pubitemid 44789912)
12. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848 (Pubitemid 44299144)
13. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
14. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
15. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745
16. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
17. Chamberlain MC (2010) Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:3988-3999
18. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260 (Pubitemid 43739717)
19. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
20. Quant E, Norden AD, Drappatz J, Ciampa A, Doherty L, LaFrankie D, Kesari S, Wen PY (2008) Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J Clin Oncol 26(15S):2008
21. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY (2010) Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 12:603-607
22. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660-668
23. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9:403-407
24. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE 2nd, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101:1986-1994
25. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12:508-516
26. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:1300-1310
27. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR, Richel DJ (2010) Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 21:1723-1727
28. Soffietti R, Trevisan E, Ruda R, Bertero L, Bosa C, Fabrini MG, Lolli I (2011) Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of Aino (Italian association of neuro-oncology). Neuro-Oncology 13:56-57
29. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107:155-164
30. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312
31. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156-163
32. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372-1380
33. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P, Gruber ML (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383-389
34. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Abrey L, Cloughesy T (2012) Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed Glioblastoma: mature progression-free survival and preliminary overall survival results in Avaglio. Neurooncol 14:101
35. Wick W, Cloughesy TF, Nishikawa R, Mason W, Saran F, Henriksson R, Hilton M, Kerloeguen Y, Chinot OL (2013) Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AV-Aglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31:2002
36. Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, Sulman EP, Mehta MP (2013) RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31:1
37. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF (2009) Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:1217-1222
38. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK (2011) Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 71:19-28
39. Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599
40. Rahman R, Smith S, Rahman C, Grundy R (2010) Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010:251231
41. Norden AD, Drappatz J, Wen PY (2009) Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5:610-620
42. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242
43. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200-1206
44. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173-180
45. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329-336
46. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586-592
47. Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11:336-344
48. Lu-Emerson C, Snuderl M, Davidson C, Kirkpatrick ND, Huang Y, Duda DG, Ancukiewicz M, Stemmer-Rachamimov A, Batchelor T, Jain RK (2012) Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma. J Clin Oncol 30:2010
49. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-1230
50. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19:929-937
51. Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O (2013) Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. doi:10.1093/neuonc/not226
52. Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M (2013) Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS ONE 8:e74345
53. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-189
54. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB (2012) Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 106:111-119
55. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB (2011) Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 105:91-101
56. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging - pilot study. Radiology 255:622-628
57. Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S (2012) Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31:33
58. Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E (2012) FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 14:649-657
59. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W (2012) 3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29-36
60. Armstrong TS, Wen PY, Gilbert MR, Schiff D (2012) Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 14:1203-1214
61. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460-468
62. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF (2008) Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 10:355-360
63. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY (2012) Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 106:121-125
64. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117:5351-5358
65. Taal W, Oosterkamp HM, Walenkamp AME, Beerepoot LV, Hanse M, Buter J, Honkoop A, Boerman D, De Vos FYFL, Jansen RL, van den Berkmortel FWPJ, Brandsma D, Kros JM, Bromberg JE, van Heuvel I, Smits M, van der Holt B, Vernhout R, van Den Bent MJ; Landelijke Werkgroep voor NeuroOncologie (2013) A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31(15S):2001
66. Field KM, Simes J, Wheeler H, Hovey EJ, Nowak AK, Cher L, Brown C, Livingstone A, Sawkins K, Rosenthal M; CABARET/COGNO Investigators (2013) A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). J Clin Oncol 31(15S):2017